REMAP-CAP is an Adaptive Platform Trial for Community-Acquired Pneumonia. A first video has been launched for a better understanding of the REMAP-CAP trial and how the adaptive platform trial works. The video shows the unique, smart, and easy-to-handle design of this trial, designed to adapt in the event of a pandemic, increasing the likelihood of patients receiving an effective treatment.
Since the COVID-19 outbreak, REMAP-CAP has extended its domains to investigate new treatments specifically for COVID-19 patients on the ICU and the ward. With the ability to improve the design according to new insights and already having the clinical trial infrastructure in place to implement these insights swiftly, various interventions can be tested simultaneously within multiple therapeutic domains.